Recent News

• 03.19.2026 - TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
• 03.09.2026 - Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
• 03.06.2026 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
• 02.26.2026 - TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
• 02.23.2026 - TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update
• 02.17.2026 - Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis
• 02.08.2026 - TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
• 02.06.2026 - TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
• 01.27.2026 - TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
• 01.13.2026 - TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones

Recent Filings

• 02.27.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - 8-K Current report
• 02.26.2026 - EX-99.1 EX-99.1
• 01.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2026 - EX-99.1 EX-99.1
• 01.13.2026 - 8-K Current report
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities